View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
June 20, 2018updated 12 Jul 2022 1:14pm

Sol-Gel doses first patient in Phase III trial of Epsolay

Sol-Gel Technologies has dosed the first patient in a pivotal Phase III clinical trial programme designed to analyse the safety and efficacy of Epsolay (formerly VERED) for the treatment of patients with papulopustular rosacea, also known as subtype II rosacea.

Sol-Gel Technologies has dosed the first patient in a pivotal Phase III clinical trial programme designed to analyse the safety and efficacy of Epsolay (formerly VERED) for the treatment of patients with papulopustular rosacea, also known as subtype II rosacea.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The programme is being carried out following Special Protocol Assessment (SPA) agreements with the US Food and Drug Administration (FDA) regarding the design of the trials.

It includes two randomised, multi-centre, double-blind, vehicle-controlled clinical trials, which are expected to enrol a total of 700 subjects at 50 sites in the US.

Each of the trials expect to include half of the enrolled subjects in a 2:1 ratio of Epsolay in comparison to its vehicle, with a power of greater than 99%.

The trials’ primary efficacy goals are success in Investigator Global Assessment (IGA), measured as a two-grade reduction in IGA on a scale of zero to four with ‘clear’ or ‘almost clear’ at week 12, and a decrease in mean inflammatory lesion count at week 12.

“Epsolay is aimed to address the need for more effective treatments for inflammatory papules and pustules of rosacea, a chronic condition for which patients often have low adherence to current drugs.”

Top-line data from both the trials are slated to be reported next year.

Sol-Gel Technologies CEO Dr Alon Seri-Levy said: “The initiation of our pivotal Phase III clinical programme for Epsolay is an important milestone in our development programme and in introducing our proprietary silica-based microencapsulation delivery system to topical drugs.

“Epsolay is aimed to address the need for more effective treatments for inflammatory papules and pustules of rosacea, a chronic condition for which patients often have low adherence to current drugs.”

Papulopustular rosacea is a chronic, inflammatory skin condition that mostly affects the face.

Epsolay is a once-daily topical cream that features encapsulated benzoyl peroxide, and has been developed using Sol-Gel’s proprietary microencapsulation technology.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena